Efficacy and safety of Yangxue Qingnao Granules in treatment of migraine: A systematic review and meta-analysis.

ABSTRACT

BACKGROUND: Yangxue Qingnao Granules (YXQN) is a Chinese patent medicine that has been commonly used in the clinical treatment of migraine. AIM: To assess the efficacy and safety of YXQN alone for the treatment of migraine. METHODS: We searched 10 databases to identify relevant randomized controlled trials (RCTs) published before September 2022. Two review authors independently searched and screened the literature, extracted the data, and assessed the methodological quality of the studies using criteria from ROB 2.0, and analyzed the data using Review Manager 5.4 software. RESULTS: A total of 12 RCTs including 767 participants with migraine met the selection criteria. We divided these studies into comparisons of YXQN with placebo, routine treatment drugs, and other Chinese patent medicines. The meta-analysis showed the following (1) Efficacy The YXQN group outperformed the placebo group [relative risk (RR) = 0.29, 95% confidence interval (95%CI) 0.15-0.43, P < 0.00001], routine treatment group (RR = 0.18, 95%CI 0.09-0.27, P < 0.0001), and Chinese patent medicine group (RR = 0.27, 95%CI 0.13-0.41, P < 0.001); (2) frequency of headache There was a significant difference between YXQN vs placebo [mean difference (MD) = -1.25, 95%CI -1.60 to -0.90, P < 0.00001], routine treatment drugs (MD = -0.85, 95%CI -1.15 to -0.56, P < 0.00001), and Chinese patent medicine (MD = -0.91, 95%CI -1.35 to -0.46, P < 0.0001); (3) headache duration We found great heterogeneity between studies, with no differences between YXQN and placebo (MD = -0.61, 95%CI -1.53 to -0.31, P = 0.19) and routine treatment drugs (MD = -0.22, 95%CI -0.89 to 0.46, P < 0.53). YXQN was more effective than other Chinese patent medicines in reducing headache duration (MD = -1.24, 95%CI -1.70 to -0.77, P < 0.00001); and (4) headache severity There was no significant difference between YXQN vs placebo (MD = -1.67, 95%CI -3.52 to 0.19, P = 0.08), routine treatment drugs (MD = -0.53, 95%CI -2.02 to 0.96, P = 0.68), and other Chinese patent medicines (MD = -0.49, 95%CI -2.83 to 1.85, P = 0.68). Mild gastrointestinal adverse reactions were reported in three cases. CONCLUSION: This study revealed that YXQN is effective and safe for treatment of migraine.